(AIM: SAR)   13 March 2012


                              SAREUM HOLDINGS PLC

                          ("Sareum" or the "Company")

                     Issue of Options & Transfer of Shares

The  Company  announces  that  it  has  granted the following share options (the
"Options")  to  Tim  Mitchell,  Chief  Executive  Officer and John Reader, Chief
Scientific Officer (together, the "Directors");

                Number of options

 Tim Mitchell           2,566,666

 John Reader            2,566,666


The  Options  have  been  granted  with  an  exercise price of 1.2 pence and are
exercisable until 13 March 2022.

Of   the   Options   granted  to  each  Director,  1,283,333 options  will  vest
immediately,  with  the  remaining  1,283,333 options  vesting  subject  to pre-
determined performance criteria.

In  addition to  the Options  being granted,  the Directors  currently each hold
options  over 12,553,846 shares, which  were granted on  13 December 2010 and 4
December 2009.

The Company also announces that Tim Mitchell has transferred 10,000,000 ordinary
shares in the capital of the Company to his wife.

Enquires:

 Sareum Holdings plc

 Tim Mitchell, Chief Executive Officer                   01223 497 700



 Merchant Securities Limited (NOMAD)

 Simon Clements                                          020 7628 2200



 Hybridan LLP (Broker)

 Claire Noyce / Deepak Reddy                             020 7947 4350



 The Communications Portfolio (Media enquiries)

 Ariane Comstive / Caolan Mahon                   020 7536 2028 / 2029
 ariane.comstive@communications-portfolio.co.uk


Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that produces
targeted  small  molecule  therapeutics,  focusing  on  cancer  and  auto-immune
disease.  Sareum aims to  successfully deliver drug  candidates for licensing to
pharmaceutical and biotechnology companies at the pre-clinical or early clinical
trials stage.

Sareum's Chk1 kinase cancer research programme is a joint research collaboration
with  The Institute of  Cancer Research and  Cancer Research Technology Limited.
The  development  candidate  resulting  from  the  collaboration  increases  the
effectiveness of current cancer therapeutics in several in-vivo cancer models.

SKIL®  (Sareum Kinase Inhibitor  Library) is Sareum's  drug discovery technology
platform  that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-
3, FLT3  & TYK2 kinase cancer and  auto-immune disease research programmes. SKIL
can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange and
trades    under    the    symbol    SAR.   For   further   information,   please
visitwww.sareum.co.uk









This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: SAREUM HOLDINGS PLC via Thomson Reuters ONE

[HUG#1593651]